Products and methods for heterologous expression of proteins in host cells

The PnlP-1 accessory protein from Mesorhizobium sp. Root 172 addresses the folding challenges in heterologous protein expression by enhancing protein yield and solubility in host cells, achieving up to 100 times improvement in protein production.

JP2024545466AInactive Publication Date: 2024-12-06ABSCI CORPORATION
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024537969
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-23
Filing Date
2022-12-13
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing methods for heterologous protein expression in host cells, such as E. coli, face challenges in properly folding and solubilizing non-native proteins due to the inefficacy of natural molecular chaperones, leading to misfolded or insoluble protein products.

Method used

Introduction of the PnlP-1 accessory protein, derived from Mesorhizobium sp. Root 172, which is encoded by a specific polynucleotide sequence, to enhance protein folding and solubility in host cells, using expression constructs with inducible or constitutive promoters and optimized for various host cells.

Benefits of technology

The PnlP-1 accessory protein significantly increases the yield of properly folded heterologous proteins by 1.5 to 100 times, as measured by assays like PhyTip-based Column Quantification and ELISA-based methods, demonstrating its effectiveness across different protein types.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545466000001
    Figure 2024545466000001
  • Figure 2024545466000002
    Figure 2024545466000002
  • Figure 2024545466000003
    Figure 2024545466000003
Patent Text Reader

Abstract

The present disclosure provides products and methods for the heterologous expression of proteins in host cells. The expression constructs, bacterial cells, and methods provided produce PnlP-1 accessory proteins that increase the yield of the heterologous protein of interest.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 63 / 293,285, filed December 23, 2021, which is incorporated by reference herein in its entirety.

[0002] The present disclosure provides products and methods for the heterologous expression of proteins in host cells. The provided expression constructs, host cells, and methods produce PnlP-1 accessory proteins that increase the yield of the heterologous protein of interest.

[0003] INCORPORATION BY REFERENCE TO SEQUENCE LISTING This application contains, as a separate part of the disclosure, a sequence listing in computer-readable form (Filename: 57385_SeqListing.XML; 3,457 bytes; Created: December 7, 2022), which is incorporated herein by reference in its entirety. [Background technology]

[0004] One of the central challenges of heterologous protein expression in host cells, such as E. coli, is the formation of misfolded protein structures or insoluble protein products. In the native E. coli system, molecular chaperone proteins mediate the proper folding of cellular proteins. Heterologous proteins expressed in E. coli generally cannot be properly folded and solubilized by native E. coli chaperones. It has been shown that expressing non-natural molecular chaperones from organisms can help mediate the proper folding of heterologous proteins. Thus, the identification of new non-natural chaperones that promote folding is an area of ​​ongoing development.

[0005] There remains a need in the art for improved host cells and methods for heterologous protein expression. Summary of the Invention [Means for solving the problem]

[0006] The present disclosure provides products and methods for producing heterologous proteins in host cells.

[0007] A protein from the Gram-negative bacterium Mesorhizobium sp. Root172 is shown herein to increase the titer of a heterologous protein of interest in a host cell, such as a bacterial host cell. The protein is referred to herein as "PnlP-1" accessory protein. This protein was previously referred to as putative alkyl hydroperoxide reductase C at www.uniprot.org / uniprot / A0A0Q8KHV0. The amino acid sequence of the PnlP-1 accessory protein is shown in SEQ ID NO:2.

[0008] The present disclosure provides an expression construct comprising: a) a polynucleotide encoding an accessory protein of SEQ ID NO:2, b) a polynucleotide encoding an accessory protein comprising an amino acid sequence at least 90% identical to SEQ ID NO:2, or c) a polynucleotide encoding an accessory protein of SEQ ID NO:2 or comprising an amino acid sequence at least 90% identical to SEQ ID NO:2, and a polynucleotide encoding a protein of interest. The accessory protein can be a Mesorhizobium sp. Root172 protein. The accessory protein can be a fusion protein comprising a heterologous signal peptide.

[0009] The polynucleotide encoding the accessory protein in the expression constructs provided herein can comprise SEQ ID NO:1. The polynucleotide encoding the accessory protein can be operably linked to a heterologous promoter. The heterologous promoter can be an inducible promoter or a constitutive promoter. The expression construct can be an extrachromosomal construct. The expression construct can further comprise one or more of the following: a heterologous promoter operably linked to the polynucleotide encoding the protein of interest; a bacterial origin of replication; and a ribosome binding site.

[0010] The protein of interest encoded by the expression constructs provided herein can be an antibody product, a T cell receptor, a chimeric antigen receptor, an enzyme, or a fragment of any of these. The protein of interest can contain one or more disulfide bonds.

[0011] The present disclosure provides a host cell comprising: a) an expression construct provided herein, or b) an expression construct provided herein that does not contain a polynucleotide encoding a protein of interest and a second expression construct that comprises a polynucleotide encoding a protein of interest. The host cell can be a prokaryotic cell. The prokaryotic host cell can be an E. coli cell. The host cell can be a eukaryotic cell. The eukaryotic host cell can be a yeast cell, an insect cell, or a mammalian cell.

[0012] The host cells provided herein can include one or more of the following: a) modified gene function of at least one gene encoding a transporter protein for an inducer of at least one inducible promoter; b) a reduced level of gene function of at least one gene encoding a protein that metabolizes the inducer of the at least one inducible promoter; c) a reduced level of gene function of at least one gene encoding a protein involved in the biosynthesis of the inducer of the at least one inducible promoter; d) modified gene function of a gene that affects the reducing / oxidizing environment of the cytoplasm of the host cell; e) a reduced level of gene function of a gene encoding a reductase; f) at least one expression construct encoding at least one disulfide bond isomerase protein; g) at least one polynucleotide encoding a form of DsbC lacking a signal peptide; and h) at least one polynucleotide encoding Ervlp.

[0013] The present disclosure provides a method for producing a protein of interest comprising incubating a host cell provided herein under conditions that allow expression of the protein of interest. The method can further comprise purifying the protein of interest.

[0014] The present disclosure also provides a method for increasing the titer of a properly folded protein of interest comprising incubating a host cell provided herein under conditions that allow expression of the protein of interest. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] As indicated above, the present disclosure provides products and methods for producing heterologous protein products in host cells.

[0016] A "host cell" herein is a cell used in bioprocessing to produce a heterologous protein product. Such a host cell can be a prokaryotic cell (e.g., a bacterial cell) or a eukaryotic cell (e.g., a yeast cell or a Chinese Hamster Ovary (CHO) cell). An E. coli host cell is exemplified herein.

[0017] As used herein with reference to a host cell, "heterologous" expression and "heterologous" protein product refer to a protein product that is not naturally expressed by the host cell. For example, a heterologous protein product refers to an accessory protein that is not naturally expressed by the host cell (e.g., the PnlP-1 accessory protein of SEQ ID NO:2 expressed in cells other than the Gram-negative bacterium Mesorhizobium sp. Root172), or a protein of interest produced in a host cell that is not naturally expressed by the host cell. "Heterologous" as used in other contexts, such as in reference to a heterologous expression control element (e.g., a promoter) operably linked to a polynucleotide encoding an accessory protein herein, indicates that the two components do not naturally occur together in that configuration in the same way.

[0018] Proteins of interest include any protein produced by bioprocessing, where the protein of interest is heterologous to the host cell. Proteins of interest include, but are not limited to, antibody products. The antibody product can be, for example, a whole antibody, a single chain variable fragment, Fv, Fab, Fab', F(ab')2, a diabody, a triabody, a tetrabody, Fd, a dAb, a minibody, or a maxibody. The antibody product can be a bispecific or multispecific antibody product.

[0019] Expression constructs

[0020] The expression constructs provided herein encode PnlP-1 accessory proteins. The same expression construct that encodes the PnlP-1 accessory protein, or a separate expression construct, can encode the heterologous protein product to be produced.

[0021] The expression constructs provided herein include, for example, the codon-optimized polynucleotide of SEQ ID NO:1 that encodes the PnlP-1 accessory protein of SEQ ID NO:2. PnlP-1 polynucleotide sequence (SEQ ID NO:1) ATGTCCCTTCGCATTAACGATATCGCCCGGACTTCACCGCTGAAACGACGCAGGGCGAAATTAAGTTTCATGATTGGATTGGGGACGGATGGGCTATTCTGTTTAGTCACCCAAAAAATTTCACGCCCGTATGCACCACTGAACTGGGTACGATGGCTGGGTT AGAAGGTGAATTTAAGAAAAGAAATGTGAAAATTATTGGCATATCTGTAGACCCTGTTGCTTCACATGACAAATGGCAGGCAGATATCAAGACAGCCACTGGACACTCAGTGCACTATCCACTTATCGGTGATAAAGACCTGAAGGTCGCCAAACTGTATGATA TGTTACCAGCCGGTGCAGGCGAAACGTCAGAAGGTCGCACCCCAGCGGATAATGCTACGGTGCGTAGTGTGTATGTAATTGGTCCGGATAAAAAAATTAAACTGGTTCTGACCTACCCTATGACGACTGGCCGCAATTTTGATGAAATTTTAAGAGCTGTTGAT TCGATGCAACTGACCGCTAAACACCAAGTTGCTACGCCGGCAAACTGGAAACAAGGAGAAGATGTTATAATCACCGCAGCCGTCTCAAATGAAGATGCAATAAAACGGTTTGGGGCGTATGAAACCATCCTTCCGTACCTGAGAAAAACTAAACAACCTAGCGCG This sequence was codon optimized via the IDT algorithm for expression in E. coli. PnlP-1 Polypeptide Sequence (SEQ ID NO:2) MSLRINDIAPDFTAETTQGEIKFHDWIGDGWAILFSHPKNFTPVCTTELGTMAGLEGEFKKRNVKIIGISVDPVASHDKWQADIKTATGHSVHYPLIGDKDLKVAKLYD MLPAGAGETSEGRTPADNATVRSVYVIGPDKKIKLVLTYPMTTGRNFDEILRAVDSMQLTAKHQVATPANWKQGEDVIITAAVSNEDAIKRFGAYETILPYLRKTKQPSA

[0022] Also provided herein is an expression construct comprising a polynucleotide encoding a PnlP-1 accessory protein activity, wherein the polynucleotide is at least 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1. As an example, the polynucleotide can be codon-optimized to include codons preferred by the host cell in which it is expressed. As another example, the polynucleotide can encode a PnlP-1 protein that contains amino acid substitutions, insertions, or deletions while retaining PnlP-1 accessory protein activity.

[0023] Assays for measuring accessory protein activity include PhyTip-based column target heterologous protein expression level quantification (phynexus.com / products / proteins / antibody-binding-phytip-columns / ), the flow cytometry-based ACE ASSAY™ (WO2021 / 146626) that measures binding probes to properly folded target protein material, and / or the ELISA-based method HiPr Binding Assay (WO2021 / 163349), which measures the fluorescent signal in a plate-based format of probes that bind to properly folded target protein. These methods measure the increase in target protein production in the presence of accessory protein compared to production levels in its absence. This increase can be at least 1.5-fold, at least two-fold, at least three-fold, at least four-fold, at least five-fold, at least six-fold, at least seven-fold, at least eight-fold, at least nine-fold, at least ten-fold, at least twenty-fold, at least fifty-fold, at least one hundred-fold, or more.

[0024] Also provided herein is an expression construct comprising a polynucleotide encoding a PnlP-1 protein with accessory protein activity, wherein the polynucleotide hybridizes under stringent conditions to SEQ ID NO:1, or a complement thereof.

[0025] The term "stringent" is used to refer to conditions generally understood as stringent in the art. Hybridization stringency is determined primarily by temperature, ionic strength, and the concentration of denaturing agents, such as formamide. Examples of stringent conditions for hybridization and washing include, but are not limited to, 0.015M sodium chloride, 0.0015M sodium citrate at 65-68°C, or 0.015M sodium chloride, 0.0015M sodium citrate, and 50% formamide at 42°C. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, (Cold Spring Harbor, NY1989).

[0026] Other expression constructs provided herein, for example, encode PnlP-1 proteins with accessory protein activity, where the proteins comprise an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the PnlP-1 accessory protein of SEQ ID NO: 2. As an example, an expression construct can encode a PnlP-1 protein with amino acid substitutions compared to SEQ ID NO: 2, but which retains PnlP-1 accessory protein activity. As another example, an expression construct can encode a PnlP-1 protein with amino acid insertions or deletions compared to SEQ ID NO: 2, but which retains PnlP-1 accessory protein activity.

[0027] As used herein, the terms "identical" and "identity" refer to a relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, as determined by aligning and comparing the sequences. "Percent identity" means the percent of identical residues between the amino acids or nucleotides in the molecules being compared, and is calculated based on the size of the smallest of the molecules being compared. For these calculations, gaps in the alignment, if any, must be addressed by a specific mathematical model or computer program (i.e., "algorithm"). Methods that can be used to calculate the identity of aligned nucleic acids or polypeptides are standard in the art. Methods can include those described in Computational Molecular Biology, (Lesk, Ed.), 1988, New York: Oxford University Press; Biocomputing Informatics and Genome Projects, (Smith, Ed.), 1993, New York: Academic Press; Computer Analysis of Sequence Data, Part I, (Griffin and Griffin, Eds.), 1994, New Jersey: Humana Press; Sequence Analysis in Molecular Biology, (von Heinje), 1987, New York: Academic Press; Sequence Analysis Primer, (Gribskov and Devereux, Eds.), 1991, New York: M. Stockton Press; and Carillo et al., SIAM J. Applied Math., 48:1073 (1988).

[0028] In calculating percent identity, the sequences being compared are aligned in a manner that gives the maximum match between the sequences. An exemplary computer program used to determine percent identity is the GCG program package, which includes GAP (Devereux et al., Nucl Acid Res, 12:387 (1984); Genetics Computer Group, University of Wisconsin, Madison, Wisc.). The computer algorithm GAP is used to align the two polypeptides or polynucleotides for which percent sequence identity is to be determined. The sequences are aligned for the best match of their respective amino acids or nucleotides (the "matched span" determined by the algorithm). The gap opening penalty (which is calculated as 3. times the average diagonal, where the "average diagonal" is the average of the diagonals of the comparison matrix being used; the "diagonal" is the score or number assigned to each perfect amino acid match by a particular comparison matrix) and gap extension penalty (which is usually 1 / 10 times the gap opening penalty), as well as a comparison matrix such as PAM250 or BLOSUM62, are used in conjunction with the algorithm. Standard comparison matrices (e.g., Dayhoff et al., Atlas of Protein Sequence and Structure, 5:345-352 (1978) for the PAM250 comparison matrix; Henikoff et al., Proc. Natl. Acad. Sci. USA, 89:10915-10919 (1992) for the BLOSUM62 comparison matrix) can also be used by the algorithm.

[0029] Recommended parameters for determining percent identity for polypeptide or nucleotide sequences using the GAP program are: Algorithm: Needleman et al., J. Mol. Biol., 48:443-453 (1970); Comparison matrix: BLOSUM62 from Henikoff et al., 1992 supra; Gap penalty: 12 (but no penalty for end gaps); Gap length penalty: 4; Similarity threshold: 0.

[0030] A particular alignment scheme for aligning two amino acid sequences may result in matching of only a short region of the two sequences, but this small aligned region may have very high sequence identity, even though there is no significant relationship between the two full-length sequences. Thus, the alignment method selected (GAP program) can be adjusted if desired to result in an alignment spanning at least 50 consecutive amino acids of the target polypeptide.

[0031] Other exemplary programs for comparing and aligning pairs of sequences include, but are not limited to, ALIGN (Myers and Miller, Comput Appl Biosci, 19, 4(1):11-17 (1988), FASTA (Pearson and Lipman, Proc Natl Acad Sci USA, 85(8):2444-2448 (1988); Pearson, Methods Enzymol, 183:63-98 (1990) and Gapped BLAST (Altschul et al., Nucleic Acids Res, 25(17):3389-40 (1997), BLASTP, BLASTN, or GCG (Devereux et al., Nucleic Acids Res, 12(1 Pt 1):387-95 (1984).

[0032] The expression constructs provided herein can encode fragments of the PnlP-1 accessory protein (SEQ ID NO:2), where the fragments retain PnlP-1 accessory protein activity.

[0033] An "expression construct" herein is a polynucleotide designed for the expression of one or more gene products of interest, and is not a naturally occurring polynucleotide molecule. An expression construct can be integrated into a host cell chromosome, or can be maintained in a host cell as a polynucleotide molecule that replicates independently of the host cell chromosome, such as a plasmid or artificial chromosome. An example of an expression construct is a polynucleotide resulting from the insertion of one or more polynucleotide sequences into a host cell chromosome, where the inserted polynucleotide sequence alters the expression of the chromosomal coding sequence. An expression vector is a plasmid expression construct that is specifically used for the expression of one or more gene products. One or more expression constructs can be integrated into a host cell chromosome, or maintained on an extrachromosomal polynucleotide, such as a plasmid or artificial chromosome. The following is a description of the various types of polynucleotide sequences that can be used in an expression construct for the expression or co-expression of gene products, including accessory proteins and protein products of interest, as described herein.

[0034] Origin of replication. In order for an expression construct to be maintained in a host cell that replicates polynucleotides independently, it must contain an origin of replication, also called a replicon. Different replicons that use the same mechanism for replication cannot always be maintained together in a single host cell through repeated cell divisions. In those cases, plasmids can be classified into incompatibility groups depending on the origin of replication they contain, as shown in Table 2 of WO2016 / 205570. Origins of replication can be selected for use in expression constructs based on incompatibility group, copy number, and / or host range, among other criteria. As described above, when two or more different expression constructs are used in the same host cell for co-expression of multiple gene products, it is best for the different expression constructs to contain origins of replication from different incompatibility groups: for example, a pMB1 replicon in one expression construct and a pl5A replicon in another. The average copy number of an expression construct in a cell relative to the number of host chromosomal molecules is determined by the origin of replication contained in that expression construct. The copy number can range from a few copies to several hundred per cell (Table 2 in WO2016 / 205570). Different expression constructs can be used that contain an inducible promoter activated by the same inducer, but that have different origins of replication. By choosing an origin of replication that maintains each different expression construct at a particular approximate copy number in the cell, it is possible to tailor the overall production level of a gene product expressed from one expression construct compared to another gene product expressed from a different expression construct. As an example, to co-express subunits A and B of a multimeric protein, an expression construct was made that contains the colEl replicon, the am promoter, and the coding sequence for subunit A expressed from the am promoter: 'colEl-Para-A.

[0035] Another expression construct is made, containing the pl 5A replicon, the am promoter, and the coding sequence for subunit B: 'pl5A-Para-B'. These two expression constructs can be maintained together in the same host cell, and expression of both subunits A and B is induced by the addition of a single inducer, arabinose, to the growth medium. If the expression level of subunit A needs to be significantly increased relative to that of subunit B, a new expression construct can be made, for example, for subunit A, but with a modified pMB1 replicon, as found in the pUC9 plasmid origin of replication ("pUC9ori"), to bring the stoichiometric ratio of the expression amounts of the two subunits closer to the desired ratio: pUC9ori-Para-A. By expressing subunit A from a high copy number expression construct, such as pUC9ori-Para-A, the amount of subunit A produced should be increased relative to expression of subunit B from pl5A-Para-B. In a similar manner, the use of an origin of replication that maintains an expression construct at a lower copy number, such as pSOOl (WO2016 / 205570), can reduce the overall level of gene product expressed from the construct. The choice of origin of replication can also determine which host cells are able to maintain an expression construct containing the replicon.For example, an expression construct containing the colEl origin of replication has a relatively narrow range of available hosts, species within the family Enterobacteriaceae, while an expression construct containing the RK2 replicon can be maintained in Escherichia coli, Pseudomonas aeruginosa, Pseudomonas putida, Azotobacter vinelandii, and Alcaligenes eutrophus, but when an expression construct contains the RK2 replicon and some regulator genes from the RK2 plasmid, it can be maintained in Sinorhizobium meliloti, Agrobacterium tumefaciens, Caulobacter crescentus, Acinetobacter calcoaceticus, and Escherichia coli. It can be maintained in a variety of host cells, such as Bacillus subtilis, Bacillus calcoaceticus, and Rhodobacter sphaeroides (Kiies and Stahl, Microbiol Rev 1989 Dec;53(4):491-516).

[0036] Similar considerations can be used to create expression constructs for inducible or co-expression in eukaryotic cells. For example, the 2 micron circle plasmid of Saccharomyces cerevisiae is compatible with plasmids from other yeast strains, such as pSRl (ATCC Accession Nos. 48233 and 66069; Araki et al., J Mol Biol 1985 Mar 20;182(2):191-203) and pKDl (ATCC Accession No. 37519; Chen et al., Nucleic Acids Res 1986 Jun 11;14(11):4471-4481).

[0037] Selection markers. Expression constructs usually contain a selection gene, also called a selection marker, which encodes a protein necessary for the survival or growth of a host cell in a selective culture medium. Host cells that do not contain an expression construct containing a selection gene will not survive in the culture medium. Typical selection genes encode proteins that confer resistance to antibiotics or other toxins or complement auxotrophic defects of the host cell. One example of a selection scheme utilizes a drug, such as an antibiotic, to stop the growth of the host cell. Those cells that contain an expression construct containing a selection marker produce a protein that confers drug resistance and survive the selection regime. Some examples of antibiotics commonly used for selection of selection markers (and abbreviations that refer to genes that provide an antibiotic resistance phenotype) are ampicillin (AmpR), chloramphenicol (CmlR or CmR), kanamycin (KanR), spectinomycin (SpcR), streptomycin (StrR), and tetracycline (TetR). Many of the plasmids in Table 2 of WO2016 / 205570 contain a selection marker, such as pBR322 (AmpR, TetR); pMOB45 (CmR, TetR); pACYClW (AmpR, KanR); and pGBMl (SpcR, StrR). The native promoter region for the selection gene is usually included as part of the selection marker portion of the expression construct, along with the coding sequence for its gene product. Alternatively, the coding sequence for the selection gene can be expressed from a constitutive promoter.

[0038] In various embodiments, suitable selectable markers include, but are not limited to, neomycin phosphotransferase (npt II), hygromycin phosphotransferase (hpt), dihydrofolate reductase (dhfr), zeocin, phleomycin, bleomycin resistance gene (ble), gentamicin acetyltransferase, streptomycin phosphotransferase, a mutant form of acetolactate synthase (als), bromoxynil nitrilase, phosphinothricin acetyltransferase (bar), enolpyruvylshikimate-3-phosphate (EPSP) synthase (aro A), muscle-specific tyrosine kinase receptor molecule (MuSK-R), copper-zinc superoxide dismutase (sod1), metallothionein (cup1, MT1), beta-lactamase (BLA), puromycin N-acetyltransferase (pac), blasticidin acetyltransferase (bls), blasticidin deaminase (bsr), histidinol dehydrogenase (HDH), N-succinyl-5-aminoimidazole-4-carboxamide ribotide (SAICAR) synthetase (ade1), argininosuccinate lyase (arg4), beta-isopropylmalate dehydrogenase (leu2), invertase (suc2), orotidine-5'-phosphate (OMP) decarboxylase (ura3), and orthologs of any of the above.

[0039] Inducible promoters. As described herein, there are several different inducible promoters that can be included in the expression construct as part of the co-expression system of the present disclosure. An inducible promoter shares at least 80% polynucleotide sequence identity, at least 90% identity, or at least 95% identity with at least 30, at least 40, or at least 50 contiguous bases of the promoter polynucleotide sequence by reference to the genomic sequence of E. coli K-12 substrain MG1655, as defined in Table 1 of WO2016 / 205570, where the percentage of polynucleotide sequence identity is determined using the method of Example 11 of WO2016 / 205570. Under "standard" induction conditions (see Example 5 of WO2016 / 205570), preferred inducible promoters have at least 75%, at least 100%, or at least 110% of the strength of the corresponding "wild-type" inducible promoter of E. coli K-12 substrain MG1655, as determined using the quantitative PCR method of De Mey et al. (Example 6 of WO2016 / 205570). Within the expression construct, the inducible promoter is positioned 5' (or "upstream") to the coding sequence for the gene product to be inducibly expressed, such that the presence of the inducible promoter directs transcription of the gene product coding sequence in the 5' to 3' direction relative to the coding strand of the polynucleotide encoding the gene product.

[0040] Below is a description of exemplary inducible promoters that can be used in expression constructs for expression or co-expression of gene products, along with some of the genetic modifications that can be made to host cells containing such expression constructs. These examples of inducible promoters and associated genes are from Escherichia coli (E. coli) strain MG1655 (American Type Culture Collection deposit ATCC 700926), which is a subline of E. coli K-12 (American Type Culture Collection deposit ATCC 10798), unless otherwise specified. Table 1 of WO / 2016 / 205570 lists the genomic location in E. coli MG1655 of the nucleotide sequences for these examples of inducible promoters and associated genes. Nucleotide and other gene sequences are referenced by genomic location in Table 1 of WO / 2016 / 205570 and are expressly incorporated herein by reference. Additional information regarding the E. coli promoters, genes, and strains described herein can be found in many public sources, including the online EcoliWiki resource, located at ecoliwiki.net.

[0041] Arabinose promoter. (As used herein, "arabinose" means L-arabinose.) Several E. coli operons involved in arabinose utilization are inducible by arabinose--araBAD, araC, arciE, and araFGH--but the terms "arabinose promoter" and "ara promoter" are typically used to designate the araBAD promoter. Several additional terms have been used to refer to the E. coli araBAD promoter, such as Para, ParaB, ParaBAD, and PBAD--. Use herein of "ara promoter" or any of the alternative terms given above means the E. coli araBAD promoter. As can be seen from the use of the alternative term "araC-araBAD promoter," the araBAD promoter is considered to be part of a bidirectional promoter, with the araBAD promoter controlling expression of the araBAD operon in one direction and the araC promoter, adjacent to and on the opposite strand from the araBAD promoter, controlling expression of the araC coding sequence in the other direction. The AraC protein is both a positive and negative transcriptional regulator of the araBAD promoter. In the absence of arabinose, the AraC protein represses transcription from the PBAD, but in the presence of arabinose, the AraC protein becomes a positive regulatory element that changes its conformation upon binding to arabinose and allows transcription from the PBAD. The araBAD operon encodes proteins that metabolize L-arabinose by converting it to D-xylulose-5-phosphate through the intermediates L-ribulose and L-ribulose phosphate. For the purpose of maximizing induction of expression from an arabinose-inducible promoter, it is useful to remove or reduce the function of AraA, which catalyzes the conversion of L-arabinose to L-ribulose, and, optionally, to remove or reduce the function of at least one of AraB and AraD.By eliminating or reducing the host cell's ability to reduce the effective concentration of arabinose in the cell, it is possible to eliminate or reduce the cell's ability to convert arabinose into other sugars, making more arabinose available for induction of arabinose-inducible promoters. Genes encoding transporters that move arabinose into the host cell are araE, which encodes the low-affinity L-arabinose proton symporter, and the araFGH operon, which encodes subunits of the ABC superfamily high-affinity L-arabinose transporter. Other proteins that can transport L-arabinose into cells are specific variants of the LacY lactose permease: the LacY(AlWC) and LacY(AlWV) proteins, which have a cysteine ​​or valine amino acid instead of alanine at position 177, respectively (Morgan-Kiss et al., Proc Natl Acad Sci USA 2002 May 28;99(11):7373-7377). To achieve uniform induction of an arabinose-inducible promoter, it is useful to make the transport of arabinose into the cell independent of regulation by arabinose. This can be achieved by removing or reducing the activity of the AraFGH transporter protein and modifying the expression of araE so that it is only transcribed from a constitutive promoter. Constitutive expression of araE can be achieved by removing or reducing the function of the native araE gene and introducing into the cell an expression construct that contains the coding sequence for the AraE protein expressed from a constitutive promoter. Alternatively, in cells lacking AraFGH function, the promoter controlling the expression of the chromosomal araE gene of the host cell can be changed from an arabinose-inducible promoter to a constitutive promoter. In a similar manner, as an additional alternative for uniform induction of an arabinose-inducible promoter, a host cell lacking AraE function can have any functional AraFGH coding sequence present in the cell expressed from a constitutive promoter.As another alternative, it is possible to express both the araE gene and the araFGH operon from a constitutive promoter by replacing the native araE and araFGH promoters with a constitutive promoter in the host chromosome. It is also possible to use a mutation in the LacY lactose permease that removes or reduces the activity of both the AraE and AraFGH arabinose transporters, allowing this protein to transport arabinose in that situation. Since expression of the lacY gene is not normally regulated by arabinose, the use of LacY mutants such as LacY(A177C) or LacY(A177V) does not lead to an "all or nothing" induction phenomenon when an arabinose-inducible promoter is induced by the presence of arabinose. The use of a polynucleotide encoding the LacY(A177C) protein is preferred over the use of a polynucleotide encoding the LacY(A177V) protein, since the LacY(A177C) protein appears to be more effective at transporting arabinose into the cell.

[0042] Propionic acid promoter. The "propionic acid promoter" or "prp promoter" is the promoter for the E. coli prpBCDE operon, also referred to as PPΦB. Like the ara promoter, the prp promoter is part of a bidirectional promoter that controls expression of the prpBCDE operon in one direction, and the prpR promoter controls expression of the prpR coding sequence in the other direction. The PrpR protein is a transcriptional regulator of the prp promoter, and activates transcription from the prp promoter when the PrpR protein binds 2-methylcitric acid ("2-MC"). Propionic acid (also called propanoic acid) is the ion of propionic acid (or propanoic acid), CH3CH2COO-, and is the smallest of the "fatty" acids with the general formula H(CH2)nCOOH that share certain properties of this class of molecules: they produce an oily layer when salinizing water, and have a soapy potassium salt. Commercially available propionic acid is generally sold as a monovalent cation salt of propionic acid, such as sodium propionate (CH3CH2COONa), or as a divalent cation salt, such as calcium propionate (Ca(CH3CH2COO)2). Propionic acid is membrane permeable and is metabolized to 2-MC by conversion of propionic acid to propionyl-CoA by PrpE (propionyl-CoA synthetase) and then conversion of propionyl-CoA to 2-MC by PrpC (2-methylcitrate synthase). Other proteins encoded by the prpBCDE operon, PrpD (2-methylcitrate dehydratase) and PrpB (2-methylisocitrate lyase), are involved in the further catabolism of 2-MC to smaller products, such as pyruvate and succinate. To maximize induction of a propionate-inducible promoter by propionate added to the cell growth medium, it is therefore desirable to have a host cell that has PrpC and PrpE activities to convert propionate to 2-MC, but also has eliminated or reduced PrpD activity, and optionally eliminated or reduced PrpB activity, to prevent 2-MC from being metabolized.Another operon encoding proteins involved in 2-MC biosynthesis is the scpA-argK-scpBC operon, also called the sbm-yg / DGH operon. These genes encode proteins required for the conversion of succinate to propionyl-CoA, which can then be converted to 2-MC by PrpC. Removal or reduction of the function of these proteins may eliminate the parallel pathway for the production of 2-MC inducer, thus reducing the background level of expression of the propionate-inducible promoter and increasing the sensitivity of the propionate-inducible promoter to exogenously supplied propionate. The deletion of sbm-ygfD-ygfG-ygfH-ygfl was introduced into E. coli BL21(DE3) to generate the JSB strain (Lee and Keasling, “A propionate-inducible expression system for enteric bacteria”, Appl Environ Microbiol 2005 Nov;71(11):6856-6862) and was useful in reducing background expression in the absence of exogenously supplied inducer, but this deletion also reduced overall expression from the prp promoter in the JSB strain. However, it should be noted that the deletion sbm-ygfD-ygfG-ygfH-ygfl also apparently affects ygfl, which encodes a putative LysR family transcriptional regulator of unknown function. The genes sbm-yg / DGH are transcribed as one operon and ygfl is transcribed from the opposite strand. The 3' ends of the ygfti and ygfl coding sequences overlap by a few base pairs, so a deletion that removed all of the sbm-yg / DGH operon also apparently removed the ygfl coding function.Removing or reducing the function of a subset of the sbm-ygfDGH gene products, such as YgfG (also called ScpB, methylmalonyl-CoA decarboxylase), or deleting most of the sbm-yg / DGH (or scpA-argK-scpBC) operon, while leaving enough of the 3' end of the ygfli (or scpC) gene so that expression of ygfl is unaffected, may be sufficient to reduce background expression from a propionate-inducible promoter without reducing the maximum level of induced expression.

[0043] Rhamnose promoter. (As used herein, "rhamnose" means L-rhamnose.) The "rhamnose promoter" or "rha promoter", or PrhaSR, is the promoter for the E. coli rhaSR operon. Like the ara and prp promoters, the rha promoter is part of a bidirectional promoter, with the rhaBAD promoter controlling expression of the rhaSR operon in one direction and the rhaBAD operon in the other direction. The rha promoter, however, has two transcriptional regulators involved in regulating expression: RhaR and RhaS. The RhaR protein activates expression of the rhaSR operon in the presence of rhamnose, while the RhaS protein activates expression of rhaBAD and rhaT, the L-rhamnose catabolic and transport operons, respectively (Wickstrum et al, J Bacteriol 2010 Jan;192(1):225-232). The RhaS protein can also activate expression of the rhaSR operon, but in fact RhaS negatively autoregulates this expression by interfering with the ability of RhaR and the cyclic AMP receptor protein (CRP) to coactivate expression to much higher levels. The rhaBAD operon encodes the rhamnose catabolic proteins RhaA (L-rhamnose isomerase), which converts L-rhamnulose to L-rhamnulose; RhaB (rhamnulokinase), which phosphorylates L-rhamnulose to form L-rhamnulose-1-P; and RhaD (rhamnulose-1-phosphate aldolase), which converts L-rhamnulose-1-P to L-lactaldehyde and DHAP (dihydroxyacetone phosphate). To maximize the amount of rhamnose in the cell available for induction of expression from a rhamnose-inducible promoter, it is desirable to reduce the amount of rhamnose that is catalytically degraded by eliminating or reducing the function of RhaA, or optionally of RhaA and at least one of RhaB and RhaD.E. coli cells can also synthesize L-rhamnose from alpha-D-glucose-1-P through the activity of the proteins RmlA, RmlB, RmlC, and RmlD (also called RfbA, RfbB, RfbC, and RfbD, respectively) encoded by the rmlBDACX (or rfbBDACX) operon. To reduce background expression from a rhamnose-inducible promoter and to enhance the sensitivity of induction of the rhamnose-inducible promoter by exogenously supplied rhamnose, it may be useful to remove or reduce the function of one or more of the RmlA, RmlB, RmlC, and RmlD proteins.

[0044] L-rhamnose is transported into the cell by RhaT, rhamnose permease or L-rhamnose:proton symporter. As described above, expression of RhaT is activated by the transcriptional regulator RhaS. To make expression of RhaT independent of induction by rhamnose (which induces expression of RhaS), the host cell can be modified so that all functional RhaT coding sequences in the cell are expressed from a constitutive promoter. In addition, the coding sequence for RhaS can be deleted or inactivated such that no functional RhaS is produced. By removing or reducing the function of RhaS in the cell, the level of expression from the rhaSR promoter increases due to the lack of negative autoregulation by RhaS, the level of expression of the rhamnose catalytic operon rhaBAD decreases, and the ability of rhamnose to induce expression from the rha promoter is further increased.

[0045] Xylose promoter. (As used herein, "xylose" means D-xylose.) Xylose promoter, or "xyl promoter", or PxyiA, refers to the promoter for the E. coli xylAB operon. The xylose promoter region is similar in organization to other inducible promoters in that both the xylAB operon and the xylFGHR operon are expressed in opposite orientations on the E. coli chromosome from adjacent xylose-inducible promoters (Song and Park, J Bacteriol. 1997 Nov;179(22):7025-7032). The transcriptional regulator of both the PxyiA and PxyiF promoters is XylR, which activates expression of these promoters in the presence of xylose. The xylR gene is expressed either as part of the xylFGHR operon or from its own weak promoter, not inducible by xylose, located between the xylH and xylR protein coding sequences. D-xylose is catabolized by XylA (D-xylose isomerase), which converts D-xylose to D-xylulose, which is then phosphorylated by XylB (xylulokinase) to form D-xylulose-5-P. To maximize the amount of xylose available in the cell for induction of expression from a xylose-inducible promoter, it is desirable to reduce the amount of xylose catalytically degraded by removing or reducing the function of at least XylA, or possibly both XylA and XylB. The xylFGHR operon encodes XylF, XylG, and XylH, subunits of the ABC superfamily high affinity D-xylose transporter. The xylE gene encodes the E. coli low affinity xylose-proton symporter and represents a separate operon, the expression of which is also inducible by xylose. To make expression of the xylose transporters independent of induction by xylose, the host cells can be engineered such that all functional xylose transporters are expressed from a constitutive promoter.For example, the xylFGHR operon can be modified such that the xylFGH coding sequence is deleted, leaving XylR as the only active protein expressed from the xylose-inducible PxyiF promoter, and the xylE coding sequence is expressed from a constitutive promoter rather than its native promoter. As another example, the xylR coding sequence is expressed from a PxyiA or promoter in an expression construct, while the xylFGHR operon is deleted and xylE is constitutively expressed, or alternatively, the xylFGH operon (lacking the xylR coding sequence because it is present in the expression construct) is expressed from a constitutive promoter and the xylE coding sequence is deleted or modified so that it does not produce an active protein.

[0046] Lactose promoter. The term "lactose promoter" refers to the lactose-inducible promoter for the lacZYA operon, also known as lacZpl; this lactose promoter is located at about 365603-365568 in the genome sequence of E. coli K-12 substrain MG1655 (NCBI Reference Sequence NC_000913.2, Jan. 11, 2012) (minus strand, with an NA polymerase binding ("-35") site at about 365603-365598, a Pribnow box ("-10") at 365579-365573, and a transcription start site at 365567). The inducible co-expression system of the present disclosure can include a lactose-inducible promoter, such as the lacZYA promoter. The inducible co-expression system of the present disclosure can include one or more inducible promoters that are not lactose-inducible promoters.

[0047] Alkaline phosphatase promoter. The terms "alkaline phosphatase promoter" and "phoA promoter" refer to the promoter for the phoApsiF operon, a promoter that is induced under conditions of phosphatase starvation. The phoA promoter region maps to about 401647-401746 (positive strand, Pribnow box ('-10') at 401695-401701 (Kikuchi et al., Nucleic Acids Res 1981 Nov 11;9(21):5671-5678)) in the genome sequence of E. coli K-12 substrain MG1655 (NCBI Reference Sequence NC 000913.3, 16 Dec. 2014). The transcriptional activator for the phoA promoter is PhoB, a transcriptional regulator that, together with the sensor protein PhoR, forms a two-component signal transduction system in E. coli. PhoB and PhoR are transcribed from the phoBR operon located at about 417050-419300 (positive strand, with the PhoB coding sequence at 417,142-417,831 and the PhoR coding sequence at 417,889-419,184) in the genomic sequence of E. coli K-12 substrain MG1655 (NCBI Reference Sequence NC000913.3, 16-Dec-2014). The phoA promoter differs from the inducible promoters described above in that it is induced by the lack of a substance - intracellular phosphate - rather than by the addition of an inducer. For this reason, the phoA promoter is generally used to direct the transcription of gene products produced at stages when the host cell is starved for phosphate, such as the later stages of fermentation. The inducible co-expression system of the present disclosure can include the phoA promoter. The inducible co-expression system of the present disclosure includes one or more inducible promoters that are not the phoA promoter.

[0048] Expression from a constitutive promoter. The expression constructs of the present disclosure can also include a coding sequence expressed from a constitutive promoter. Unlike inducible promoters, constitutive promoters initiate continuous production of a gene product under most growth conditions. One example of a constitutive promoter is that of the Tn3 bla gene, which encodes beta-lactamase and is responsible for the ampicillin resistance (AmpR) phenotype conferred on host cells by many plasmids, including pBR322 (ATCC31344), pACYClW (ATCC37031), and pBAD24 (ATCC87399). Another constitutive promoter that can be used in the expression construct is the promoter for the E. coli lipoprotein gene, which maps to positions 1755731-1755406 (plus strand) in E. coli K-12 substrain MG1655 (Inouye and Inouye, Nucleic Acids Res 1985 May 10; 13(9): 3101-3110). A further example of a constitutive promoter that has been used for heterologous gene expression in E. coli is the trpLEDCBA promoter, which maps to positions 1321169-1321133 (minus strand) in E. coli K-12 substrain MG1655 (Windass et al., Nucleic Acids Res 1982 Nov 11; 10(21): 6639-6657). Constitutive promoters can be used in expression constructs for the expression of selectable markers, as described herein, and also for the constitutive expression of other gene products useful for co-expression of a desired product. For example, inducible promoters, such as transcriptional regulators, such as AraC, PrpR, RhaR, and XylR, if not expressed from a bidirectional inducible promoter, can alternatively be expressed from a constitutive promoter, either in the same expression construct as the inducible promoter they regulate, or in a different expression construct. Similarly, inducers, gene products useful for production or transport, such as PrpEC, AraE, or Rha, or proteins that modify the reduction-oxidation environment of the cell, as a few examples, can be expressed from constitutive promoters in expression constructs.Co-expressed gene products, and the resulting gene products useful for producing a desired product, also include accessory proteins, cofactor transporters, and the like.

[0049] Ribosome Binding Site. For a polypeptide gene product, the nucleotide sequence of the region between the transcription initiation site and the start codon of the coding sequence of an inducibly expressed gene product corresponds to the 5' untranslated region ("UTR") of the mRNA for the polypeptide gene product. The region of the expression construct corresponding to the 5'UT can contain a polynucleotide sequence similar to a consensus ribosome binding site (RBS, also called a Shine-Dalgarno sequence) found in the host cell species. In prokaryotes (archaea and bacteria), the RBS consensus sequence is GGAGG or GGAGGU, and in bacteria, such as E. coli, the RBS consensus sequence is AGGAGG or AGGAGGU. The RBS is typically separated from the start codon by 5-10 intervening nucleotides. In the expression construct, the RBS sequence is at least 55% identical, at least 70% identical, or at least 85% identical to the AGGAGGU consensus sequence and is separated from the start codon by 5-10 intervening nucleotides, 6-9 intervening nucleotides, or 6-7 intervening nucleotides. The ability of a given RBS to produce a desired translation initiation rate can be calculated using the RBS calculator at the website salis.psu.edu / software / RBSLibraryCalculatorSearchMode; the same tool can be used to optimize synthetic RBSs for translation rate over a 100,000+ fold range (Salis, Methods Enzymol 2011;498:19-42).

[0050] Multiple Cloning Site. A multiple cloning site (MCS), also called a polylinker, is a polynucleotide that contains multiple restriction sites adjacent to or overlapping each other. Restriction sites in an MCS typically occur once within the MCS sequence and preferably do not occur within the remainder of a plasmid or other polynucleotide construct, allowing restriction enzymes to cut the plasmid or other polynucleotide construct only within the MCS. Examples of MCS sequences are those contained in the pBAD series of expression vectors, including pBAD18, pBAD18-Cm, pBAD18-Kan, pBAD24, pBAD28, pBAD30, and pBAD33 (Guzman et al., J Bacteriol 1995 Jul;177(14):4121-4130); or in the pPRO series of expression vectors derived from the pBAD vectors, such as pPR018, pPR018-Cm, pPR018-Kan, pPR024, pPRO30, and pPR033 (U.S. Patent No. 8,178,338 B2; May 15, 2012; Keasling, Jay). Multiple cloning sites can be used in the creation of expression constructs by placing the multiple cloning site 3' (or downstream) of a promoter sequence, but using the MCS to insert coding sequences for gene products to be expressed or co-expressed into the construct at the appropriate location relative to the promoter so that transcription of the coding sequence occurs. Depending on which restriction enzyme is used to cut within the MCS, there may be some portion of the MCS sequence that remains in the expression construct after a coding sequence or other polynucleotide sequence is inserted into the expression construct. Any remaining MCS sequence may be upstream or downstream of the insert sequence, or on either side of it. The ribosome binding site may be located upstream or immediately adjacent to the MCS, or may be separated from the MCS by only a few nucleotides, in which case the RBS may be upstream of any coding sequence inserted into the MCS. Another alternative is to include the ribosome binding site within the MCS, in which case the choice of restriction enzyme used to cut within the MCS will determine whether the RBS is retained and in what relationship to the insert sequence.A further alternative is to include an RBS within a polynucleotide sequence inserted into an expression construct at the MCS, in appropriate relationship to any coding sequence to stimulate initiation of translation from a transcribed messenger RNA.

[0051] Signal peptides. Polypeptide gene products expressed or co-expressed by the disclosed methods can contain or lack a signal peptide, depending on whether it is desired that such gene products be transported from the cytoplasm into the periplasm or retained in the cytoplasm, respectively, of the host cell. Signal peptides (also called signal sequences, leader sequences, or leader peptides) are structurally characterized by a stretch of hydrophobic amino acids, about 5-20 amino acids long, often about 10-15 amino acids long, that has a tendency to form a single alpha-helix. This hydrophobic stretch is often immediately preceded by a shorter stretch rich in positively charged amino acids, especially lysines. Signal peptides that are cleaved from mature polypeptides typically end with a stretch of amino acids that is recognized and cleaved by a signal peptidase. Signal peptides can be functionally characterized by their ability to direct the transport of the polypeptide, either co-translationally or post-translationally, through the cell membrane of prokaryotes (or the inner membrane of gram-negative bacteria such as E. coli) or into the endoplasmic reticulum of eukaryotic cells. The extent to which a signal peptide enables a polypeptide to be transported into the periplasmic space of a host cell, such as E. coli, can be determined by separating periplasmic proteins from proteins retained in the cytoplasm using methods such as those described in Example 12 of WO2016 / 205570.

[0052] host cell

[0053] The host cells provided herein contain one or more expression constructs described herein.

[0054] Prokaryotic host cells. Host cells are provided, including expression constructs designed to express heterologous gene products (such as accessory proteins described herein) in host cells, including but not limited to prokaryotic host cells. Prokaryotic host cells may be selected from the group consisting of Archaea (e.g., Haloferax volcanii, Sulfolobus solfataricus), Gram-positive bacteria (e.g., Bacillus subtilis, Bacillus licheniformis, Brevibacillus choshinensis, Lactobacillus brevis, Lactobacillus buchneri, Lactococcus lactis, and Streptomyces lividans), or alphaproteobacteria (e.g., Agrobacterium tumefaciens). tumefaciens, Caulobacter crescentus, Rhodobacter sphaeroides, and Sinorhizobium meliloti), Betaproteobacteria (Alcaligenes eutrophus), and Gammaproteobacteria (Acinetobacter calcoaceticus, Azotobacter vinelandii, Escherichia coli, Pseudomonas aeruginosa, and Pseudomonas putida).Such host cells include gammaproteobacteria of the Enterobacteriaceae family, such as Enterobacter, Erwinia, Escherichia (including E. coli), Klebsiella, Proteus, Salmonella (including Salmonella typhimurium), Serratia (including Serratia marcescans), and Shigella.

[0055] As described in WO2017 / 106583, which is incorporated herein by reference in its entirety, producing gene products, such as therapeutic proteins, on a commercial scale and in soluble form is addressed by providing suitable host cells capable of growth at high cell densities, for example in fermentation cultures, and capable of producing soluble gene products in the cytoplasm of oxidizing host cells through highly controlled inducible gene expression. Host cells of the present disclosure with these qualities are produced by combining some or all of the following features: (1) The host cells are genetically modified to have an oxidizing cytoplasm through increasing the expression or function of an oxidizing polypeptide in the cytoplasm and / or by decreasing the expression or function of a reducing polypeptide in the cytoplasm. Specific examples of such genetic modifications are provided herein. Optionally, the host cells can also be genetically modified to express accessory proteins and / or cofactors that aid in the production of the desired gene product and / or to glycosylate the polypeptide gene product. (2) The host cells contain one or more expression constructs designed for the expression of one or more gene products of interest. At least one expression construct comprises an inducible promoter and a polynucleotide encoding a gene product expressed from the inducible promoter. (3) The host cell contains additional genetic modifications designed to improve particular aspects of gene product expression from the expression construct.The host cell has (A) an alteration of gene function of at least one gene encoding a transporter protein for an inducer of at least one inducible promoter, in another example, where the gene encoding the transporter protein is selected from the group consisting of araE, araE, araG, araH, rhaT, xylF, xylG, and xylH, or in particular araE, or in which more specifically, the alteration of gene function is expression of araE from a constitutive promoter, and / or (B) an alteration of gene function of at least one gene encoding a protein that metabolizes an inducer of at least one inducible promoter. and / or (C) having a reduced level of gene function of at least one gene encoding a protein involved in the biosynthesis of an inducer of at least one inducible promoter, and, as further examples, wherein the genes encoding proteins that metabolize an inducer of at least one of the inducible promoters are araA, araB, araD, prpB, prpD, rhaA, rhaB, rhaD, xylA, and xylB, and / or (D) having a reduced level of gene function of at least one gene encoding a protein involved in the biosynthesis of an inducer of at least one inducible promoter, which genes are further selected from scpA / sbm, argK / ygfD, scpB / ygfG, scpC / ygfH, rmlA, rmlB, rmlC, and rmlD.

[0056] Host cells with oxidized cytoplasm. Host cells are provided that allow efficient and cost-effective expression of gene products, including components of multimeric products. Host cells can include isolated cells in culture as well as cells that are part of a multicellular organism or cells grown in different organisms or systems of organisms. In certain embodiments of the present disclosure, the host cell is a microbial cell, such as a yeast (Saccharomyces, Schizosaccharomyces, etc.), or a bacterial cell, or a Gram-positive or Gram-negative bacterium, or an E. coli, or an E. coli B strain, or an E. coli (B strain) EB0001 cell (also called an E. coli ASE (DGH) cell), or an E. coli (B strain) EB0002 cell. Growth experiments with E. coli host cells with an oxidizing cytoplasm, specifically E. coli B strains SHuffle® Express (NEB Catalog No. C3028H) and SHuffle® T7 Express (NEB Catalog No. C3029H) and E. coli K strain SHuffle® T7 (NEB Catalog No. C3026H), have shown that these E. coli B strains with an oxidizing cytoplasm can grow to much higher cell densities than their closest corresponding E. coli K strains (WO 2017 / 106583).

[0057] Modifications to host cell gene functions. Certain modifications can be made to gene functions of host cells containing inducible expression constructs to facilitate efficient and uniform induction of a host cell population by an inducer. The combination of expression construct, host cell genotype, and induction conditions can result in at least 75%, at least 85%, or at least 95% of the cells in the culture expressing the gene product from each inducible promoter, as measured by the method of Khlebnikov et al., described in Example 9 of WO2017 / 106583. For host cells other than E. coli, these modifications can include functions of genes that are structurally similar to E. coli genes or that perform functions in the host cell that are similar to the functions of E. coli genes. Modifications to host cell gene functions include removing or reducing gene functions by deleting the gene protein coding sequence in its entirety or deleting a sufficiently large portion of the gene, inserting a sequence into the gene, or otherwise modifying the gene sequence such that a reduced level of functional gene product is produced from that gene. Modifications to host cell gene function also include increasing gene function, for example, by modifying a native promoter to create a stronger promoter that drives higher levels of transcription of the gene, or by introducing a missense mutation in a protein coding sequence that results in a more highly active gene product. Modifications to host cell gene function include modifying gene function in any way, including, for example, modifying a native inducible promoter to create a constitutively activated promoter. In addition to modifications in gene functions for transport and metabolism of inducers and / or modified expression of accessory proteins as described herein in connection with inducible promoters, it is also possible to modify the reduced-oxidative environment of the host cell.

[0058] Host cell reducing and oxidizing environment. In bacterial cells, such as E. coli, proteins that require disulfide bonds are typically transported into the periplasm, where disulfide bond formation and isomerization are catalyzed by the Dsb system, including DsbABCD and DsbG. Increased expression of the cysteine ​​oxidase DsbA, the disulfide isomerase DsbC, or a combination of Dsb proteins, all of which are normally transported into the periplasm, has been utilized in the expression of heterologous proteins that require disulfide bonds (Makino et al., Microb Cell Fact 2011 May 14;10:32). It is also possible to express cytoplasmic forms of these Dsb proteins, such as cytoplasmic versions of DsbA and / or DsbC ('cDsbA or 'cDsbC'), that lack the signal peptide and thus are not transported into the periplasm. Cytoplasmic Dsb proteins, such as cDsbA and / or cDsbC, are useful for making the host cell cytoplasm more oxidized, thus contributing to the formation of disulfide bonds in heterologous proteins produced in the cytoplasm. The host cell cytoplasm can also be made less reducing and thus more oxidized by directly modifying the thioredoxin and glutaredoxin / glutathione enzyme systems: mutants defective in glutathione reductase (gor) or glutathione synthetase (gshB), together with thioredoxin reductase (trxB), confer cytoplasmic oxidation. These strains are unable to degrade ribonucleotides and therefore unable to grow in the absence of exogenous reducing agents, such as dithiothreitol (DTT).Suppressor mutations in the gene ahpC encoding AhpC (e.g., ahpC* and ahpCA, Lobstein et al., Microb Cell Fact 2012 May 8;11:56;doi:10.1186 / 1475-2859-11-56) convert it into a disulfide reductase that generates reduced glutathione, allowing channeling of electrons onto the enzyme ribonucleotide reductase, allowing cells defective in gor and trxB, or defective in gshB and trxB, to grow in the absence of DTT. Different classes of mutant forms of AhpC can allow strains defective in the activity of gamma-glutamylcysteine ​​synthetase (gshA) and defective in trxB to grow in the absence of DTT; these include AhpC V164G, AhpC S71F, AhpC E173 / S71F, AhpC E171Ter, and AhpC dupl62-169 (Faulkner et al., Proc Natl Acad Sci USA 2008 May 6;105(18):6735-6740, Epub 2008 May 2). In such strains with an oxidative cytoplasm, exposed protein cysteines are readily oxidized in a process catalyzed by thioredoxin, resulting in the formation of disulfide bonds in the reversal of their physiological function. Other proteins that may be useful for reducing the effects of oxidative stress in an oxidized cytoplasmic host cell are HPI (hydroperoxidase I) catalase peroxidase, encoded by E. coli katG, and HPII (hydroperoxidase II) catalase peroxidase, encoded by E. coli katE, which disproportionate peroxide into water and oxygen (Farr and Kogoma, Microbiol Rev. 1991 Dec;55(4):561-585; Review). Increasing levels of KatG and / or KatE proteins in a host cell, either through induced co-expression or through elevated levels of constitutive expression, are contemplated herein.

[0059] Another modification that can be made to the host cell is to express the sulfhydryl oxidase Ervlp from the inner membrane space of yeast mitochondria in the cytoplasm of the host cell, which has been shown to increase production of a variety of complex disulfide-bonded proteins of eukaryotic origin in the cytoplasm of E. coli, even in the absence of mutations in gor or trxB (Nguyen et al, Microb Cell Fact 2011 Jan 7;10:1).

[0060] Host cells containing the expression constructs can also express cDsbA and / or cDsbC and / or Ervlp; be deficient in trxB gene function; be deficient in any of gor, gshB, or gshA gene function; optionally have increased levels of katG and / or katE gene function; and express a suitable mutant form of AhpC such that the host cells are capable of growth in the absence of DTT.

[0061] Chaperone proteins. A gene product of interest can be co-expressed with other gene products, such as chaperone proteins, that are beneficial to the production of the desired gene product. Chaperone proteins are proteins that assist in the non-covalent folding or unfolding, and / or assembly or degradation of other gene products, but do not occur in the resulting monomeric or multimeric gene product structures when the structures are performing their normal biological functions (completing the folding and / or assembly process). Chaperone proteins can be expressed from inducible or constitutive promoters in expression constructs, or can be expressed from host cell chromosomes; expression of the chaperone proteins in the host cell is at a high enough level to produce the co-expressed gene products that are properly folded and / or assembled into the desired product. Examples of chaperone proteins present in E. coli host cells are folding factors DnaK / DnaJ / GrpE, DsbC / DsbG, GroEL / GroES, IbpA / IbpB, Skp, Tig (trigger factor), and FkpA, which have been used to prevent protein aggregation of cytoplasmic or periplasmic proteins. It has been shown that DnaK / DnaJ / GrpE, GroEL / GroES, and ClpB can function synergistically in assisting protein folding, and thus expression of these chaperone proteins in combination is beneficial for protein expression (Makino et al., Microb Cell Fact 2011 May 14;10:32). When expressing eukaryotic proteins in prokaryotic host cells, eukaryotic chaperone proteins, such as protein disulfide isomerase (PDI) from the same or related eukaryotic species, are co-expressed or inducibly co-expressed with the desired gene product.

[0062] One chaperone that can be expressed in a host cell is the protein disulfide isomerase from the soil imperfect fungus (soft rot fungus) Humicola insolens. The amino acid sequence of Humicola insolens PDI is shown as SEQ ID NO:1 in WO2017 / 106583; it lacks the signal peptide of the native protein so that it remains in the cytoplasm of the host cell. The nucleotide sequence encoding PDI was optimized for expression in E. coli; an expression construct for PDI is shown as SEQ ID NO:2 in WO2017 / 106583. SEQ ID NO:2 in WO2017 / 106583 contains a GPAGC Nhel restriction site at its 5' end, an AGGAGG ribosomal binding site at nucleotides 7-12, a PDI coding sequence at nucleotides 21-1478, and a GTCGAC Sail restriction site at its 3' end. The nucleotide sequence of SEQ ID NO:2 of WO2017 / 106583 was designed to be inserted immediately downstream of a promoter, such as an inducible promoter. The Nhel and Sail restriction sites in SEQ ID NO:2 of WO2017 / 106583 can be used to insert it into a multiple cloning site of a vector, such as the multiple cloning site of the pSOL expression vector (SEQ ID NO:3 of WO2017 / 106583) described in published U.S. patent application US2015353940A1, which is incorporated herein by reference in its entirety. Other PDI polypeptides can also be expressed in host cells, including PDI polypeptides from various species (Saccharomyces cerevisiae (UniProtKB PI7967), Homo sapiens (UniProtKB P07237), Mus musculus (UniProtKB P09103), Caenorhabditis elegans (UniProtKB Q17770 and Q17967), Arabidopsis thaliana (UniProtKB 048773, Q9XI01, Q9S G3, Q9LJU2, Q9MAU6, Q94F09, and Q9T042), Aspergillus niger (UniProtKB Q12730), as well as modified forms of such PDI polypeptides.A PDI polypeptide expressed in a host cell of the present disclosure may have at least 70%, or 80%, or 90%, or 95% amino acid sequence identity over at least 50% (or at least 60%, or at least 70%, or at least 80%, or at least 90%) of the length of SEQ ID NO:1 of WO2017 / 106583, where the amino acid sequence identity is determined according to Example 10 of WO2017 / 106583.

[0063] Cellular Transport of Cofactors. When using the expression systems of the present disclosure to produce enzymes that require cofactors for function, it is useful to use host cells that can synthesize the cofactor from available precursors or take it up from the environment. Common cofactors include ATP, coenzyme A, flavin adenine dinucleotide (FAD), NAD+ / NADH, and heme. Polynucleotides encoding cofactor transporting and / or cofactor synthesising polypeptides can be introduced into the host cell, and such polypeptides can be constitutively expressed or inducibly co-expressed with the gene products produced by the methods of the present disclosure.

[0064] Glycosylation of polypeptide gene products. Host cells can have alterations in their ability to glycosylate polypeptides. For example, eukaryotic host cells can have deleted or reduced gene functions in glycosyltransferase genes and / or oligo-saccharyltransferase genes, impairing normal eukaryotic glycosylation of polypeptides to form glycoproteins. Prokaryotic host cells, such as E. coli, do not normally glycosylate polypeptides and can be modified to express a set of eukaryotic and prokaryotic genes that provide glycosylation functions (DeLisa et al., WO2009 / 089154A2, 2009 Jul 16).

[0065] Available host cell lines with modified gene functions. To generate preferred strains of host cells for use in the expression systems and methods of the present disclosure, it is useful to start with a strain that already contains the desired genetic modifications (see Table A of WO2017 / 106583, reproduced below). [Table 1-1] [Table 1-2]

[0066] Assays for accessory protein activity

[0067] Accessory protein activity can be measured, for example, by the following assays: For example, the accessory protein activity of a PnlP-1 variant or fragment can be demonstrated by one or more of the assays.

[0068] Exemplary ACE Assay Protocol (Based on the Assay in WO2021 / 146626) 1. The sample cells are fixed using a formaldehyde-based solution. 2. Prepare permeabilization buffer and treat cells. 3. Add biotin to 1×PE+1 mM EDTA to a final concentration of 0.1 mg / ml biotin. 4. Add biotin (stored at -80°C or 4°C) at a 100-fold dilution (e.g., 5000uL or 5mL PE buffer may require 50uL biotin). 5. Combine the fluorescently labeled primary probe (and secondary probe, if dual probe) in 1xPE+1m MEDTA in a 15 mL centrifuge tube (or 50 mL if the volume of staining reagent exceeds 15 mL). 6. Incubate and rotate for at least 1 hour at 4° C. with foil wrapped around the tube. 7. After 1 hour, add biotin to the staining solution to a final concentration of 0.1 mg / ml biotin. 8. Add biotin (stored at -80 or 4°C) at a 100x dilution. For example, 5000 μL or 5 mL of PE buffer may require 50 μL of biotin). Incubate again with foil wrapped around the tube and with rotation for at least 30 minutes. 9. Spin samples at 3300g for 5 minutes at 4°C. 10. Aspirate the supernatant using a vacuum pump and matrix tube attachment, avoid touching the side of the tube with the attachment. 11. Without disturbing the pellet, slowly step 500 μL of 1X PBS + 1 mM EDTA down the side of the sample tube. 12. Add 250 μL of E2 fixation buffer to each tube. 13. After 18 hours of incubation, remove samples from the rotator and spin in a centrifuge at 3300 g for 3 minutes at 4°C. 14. Perform FACS on stained cell samples and bin by fluorescent signal.

[0069] Exemplary HiPR Binding Assay (Based on the Assay in WO2021 / 163349) 1. Cultivate sample cells in appropriate inducing conditions to promote expression of the target protein and accessory proteins. Ie Arabinose and / or propionate medium. Grow sample cells in 96-well plates. 2. Keep sample plates on ice and allow to thaw. While they are thawing, assemble and label the plates needed and prepare the assay solutions. 3. Dilute the standards in Dilution Buffer 1 solution (0.1x Perkin Elmer Buffer, 1 mM EDTA, 1x PBS). 4. Prepare Assay Solution I (ASI) and Assay Solution II (ASII) in dark amber 50 mL conicals. 5. Dispense Dilution Buffer 2 into a 384-well V-bottom Greiner Bio-One dilution plate and resuspend the cell pellet. 6. Dispense ASI into 384 well proxy plate. Visually inspect that the silicon nozzles are properly seated and that nothing appears loose or off the quill. 7. Once each plate is completed, seal it using a Perkin Elmer plate sealer. 8. Spin the plate down at 500g for 1 minute. 9. Incubate the plate at 4°C overnight. 10. The next day, remove plates from 4° C. storage. Allow to equilibrate to room temperature for at least 1 hour. 11. Feed the plates into the plate feeder on the Enspire. 12. Scan on Enspire using “Alpha,FI-DNA_Ex480 Em520-Alpha384-SW”. 13. Record the value for further analysis of the Alpha Max Slope.

[0070] Other Terminology and Disclosures

[0071] Where a range of values ​​is provided herein, it is understood that each intervening value, to the tenth of the unit of the lower limit, is encompassed within the disclosure, unless the context clearly dictates otherwise, between the upper and lower limits of that range and any other stated or intervening value in that stated range. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the disclosure, subject to any specifically excluded limits in the stated range. Where a stated range includes one or both of the limits, ranges excluding either one or both of those included limits are also included within the disclosure.

[0072] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of this disclosure, the preferred methods and materials are described herein. All publications mentioned herein are incorporated by reference to disclose and describe the methods and / or materials in the context in which the publications are cited.

[0073] As used herein and in the appended claims, the singular forms "a," "and," and "the" include plural referents unless the context clearly dictates otherwise. Note that the claims may be drafted to exclude any element, e.g., any optional element. As such, this statement is intended to serve as a priori basis for the use of exclusive terminology such as "solely," "only," and the like in connection with the recitation of claim elements or the use of "negative" limitations.

[0074] As will be apparent to one of ordinary skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has separate components and features that can be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the disclosure. Any recited method can be carried out in the order of events recited or in any other order that is logically possible. This disclosure is intended to provide support for all such combinations.

[0075] As used herein, "can include" or "can be" refers to something contemplated by the inventors to be functional and usable as part of the subject matter provided.

[0076] While the following examples describe specific embodiments, variations and modifications will occur to those skilled in the art. Accordingly, only limitations appearing in the claims should be placed on the invention. EXAMPLES

[0077] The following experiments identified accessory proteins that significantly increased the titers of three different proteins expressed in heterologous host cells.

[0078] Example 1 E. coli host cells expressing Fab molecules (referred to herein as Fab1) were transformed with two plasmid accessory protein libraries derived from DENOVIUM ENGINE and cultivated through the AMBR fermentation system (Sartorius). Using the ACE assay described in WO2021 / 146626, the resulting host cells were binned and sorted across a distribution of specific cellular activities. Plasmid DNA from cells in each activity bin was extracted and sequenced using shotgun sequencing (Illumina). Sequencing reads were computationally aligned to accessory protein coding sequences in the accessory protein library. Fractional read abundance was measured, and enrichment scores and p-values ​​were calculated based on the fractional abundance of each accessory protein across all activity bins.

[0079] For Fab1 molecules, the two libraries share a small number of high enrichment score accessory proteins, one of which includes the amino acid sequence of SEQ ID NO:2, a sequence previously predicted by homology to encode the peroxidase referred to above. A host cell line expressing this protein was chosen for further evaluation of its activity as an accessory protein to enhance production of Fab1 in host cells.

[0080] Example 2 Based on the ACE enrichment analysis described above, eleven individual host cell strains containing plasmids with different combinations of accessory proteins, including the protein of SEQ ID NO:2, were grown using the Ambr® Fermentation System. Each strain was grown in duplicate. Each strain was assayed for Fab1 titer using an antibody-conjugated PhyTip column at different sampling time points during the fermentation run.

[0081] Three strains containing a plasmid encoding the protein of SEQ ID NO:2, designated herein as the "PnlP-1" accessory protein, showed increased protein production over the positive control strain.

[0082] Example 3 Using the same host cells, plasmid library, and methods as in Example 1, accessory protein enrichment scores were calculated via ACE for another Fab molecule (referred to herein as Fab2).

[0083] When comparing the enrichment scores for Fab1 and Fab2 molecules, there were some accessory proteins that appeared in the lowest scoring set for both Fab1 and Fab2 molecules, as well as some accessory proteins that appeared in the highest scoring set for both Fab1 and Fab2 molecules. The host cell line expressing the PnlP-1 accessory protein was again represented in the highest scoring set, indicating its utility for increasing expression across different Fab molecules.

[0084] Example 4 An ELISA-based method was used to evaluate the titer of another heterologous protein, an Fc fusion molecule, produced in the same type of E. coli host cells. The method was applied to an E. coli strain containing multiple accessory protein plasmids that expressed an Fc fusion molecule (referred to herein as Fc fusion 1). The strain was grown in 96-well 1 ml deep-well plates. The strain was grown and tested in triplicate. The cell culture was harvested and lysed as input for the ELISA test.

[0085] The host cell line with the highest ELISA signal for the Fc fusion 1 molecule expressed the PnlP-1 accessory protein, indicating the utility of this accessory protein to increase expression across different heterologous protein biological classes.

[0086] All documents mentioned in this application are incorporated herein by reference in their entirety.

Claims

1. 1. An expression construct comprising: a) a polynucleotide encoding the accessory protein of SEQ ID NO:2; b) a polynucleotide encoding an accessory protein comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:2; or c) An expression construct comprising a polynucleotide encoding an accessory protein of SEQ ID NO:2 or an accessory protein comprising an amino acid sequence at least 90% identical to SEQ ID NO:2, and a polynucleotide encoding a protein of interest.

2. The expression construct of claim 1 , wherein the accessory protein is a Root172 protein of Mesorhizobium sp.

3. The expression construct of claim 1 or 2, wherein the accessory protein comprises SEQ ID NO:

2.

4. 4. The expression construct of claim 1, 2, or 3, wherein the accessory protein is a fusion protein containing a heterologous signal peptide.

5. The expression construct of claim 1 , 2, 3, or 4, wherein the polynucleotide encoding the accessory protein comprises SEQ ID NO:

1.

6. The expression construct of claim 1 , 2, 3, 4, or 5, wherein the polynucleotide encoding the accessory protein is operably linked to a heterologous promoter.

7. The expression construct of claim 6 , wherein the heterologous promoter is an inducible promoter or a constitutive promoter.

8. The expression construct of claim 1, 2, 3, 4, 5, 6 or 7, wherein the expression construct is an extrachromosomal construct.

9. 9. The expression construct of claim 1, 2, 3, 4, 5, 6, 7, or 8, further comprising one or more of a heterologous promoter, a bacterial origin of replication, and a ribosome binding site.

10. 10. The expression construct of claim 1, 2, 3, 4, 5, 6, 7, 8, or 9, wherein the protein of interest is an antibody product, a T cell receptor, a chimeric antigen receptor, an enzyme, or a fragment of any thereof.

11. 11. The expression construct of claim 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, wherein the protein of interest comprises one or more disulfide bonds.

12. A host cell comprising: a) an expression construct according to any one of claims 1 to 11, or b) A host cell comprising an expression construct according to any one of claims 1 to 11 which does not contain a polynucleotide encoding a protein of interest and a second expression construct which comprises a polynucleotide encoding a protein of interest.

13. The host cell of claim 12 , wherein the host cell is a prokaryotic cell.

14. The host cell of claim 13 , wherein the host cell is an E. coli cell.

15. The host cell of claim 14 , wherein the host cell is a eukaryotic cell.

16. The host cell of claim 15 , wherein the host cell is a yeast cell, an insect cell, or a mammalian cell.

17. The cells, a) modifying the gene function of at least one gene encoding a transporter protein for an inducer of at least one inducible promoter; b) a reduced level of gene function of at least one gene encoding a protein that metabolizes an inducer of at least one inducible promoter; c) a reduced level of gene function of at least one gene encoding a protein involved in the biosynthesis of an inducer of at least one inducible promoter; d) altered gene function of genes that affect the reducing / oxidizing environment of the cytoplasm of the host cell; e) a reduced level of gene function of the gene encoding reductase; f) at least one expression construct encoding at least one disulfide bond isomerase protein; g) at least one polynucleotide encoding a form of DsbC lacking a signal peptide; and h) at least one polynucleotide encoding an Ervlp.

18. 20. A method for producing a protein of interest, comprising incubating a host cell according to claim 10, 11, 12, 13, 14, 15, 16 or 17 under conditions allowing expression of said protein of interest.

19. 20. The method of claim 18, further comprising purifying the protein of interest.

20. 20. A method for increasing the titer of a properly folded protein of interest, comprising incubating a host cell according to claim 10, 11, 12, 13, 14, 15, 16 or 17 under conditions allowing expression of the protein of interest.